Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.63 Million SEK | -194.45% |
| 2022 | 5.96 Million SEK | 113.79% |
| 2021 | -43.24 Million SEK | -4720.59% |
| 2020 | 936 Thousand SEK | 115.53% |
| 2019 | -6.02 Million SEK | -459.57% |
| 2018 | -1.07 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | -5.63 Million SEK | -56.71% |
| 2023 Q3 | -3.59 Million SEK | 38.36% |
| 2023 Q1 | -40.3 Million SEK | -775.93% |
| 2023 Q2 | -5.83 Million SEK | 85.53% |
| 2023 FY | -5.63 Million SEK | -194.45% |
| 2022 Q1 | -32.76 Million SEK | 24.23% |
| 2022 Q4 | 5.96 Million SEK | 125.25% |
| 2022 FY | 5.96 Million SEK | 113.79% |
| 2022 Q3 | -23.61 Million SEK | 18.96% |
| 2022 Q2 | -29.13 Million SEK | 11.09% |
| 2021 Q4 | -43.24 Million SEK | 19.25% |
| 2021 FY | -43.24 Million SEK | -4720.59% |
| 2021 Q3 | -53.55 Million SEK | -1483.62% |
| 2021 Q1 | -21.93 Million SEK | -2443.36% |
| 2021 Q2 | -3.38 Million SEK | 84.58% |
| 2020 Q4 | 936 Thousand SEK | 0.0% |
| 2020 FY | 936 Thousand SEK | 115.53% |
| 2020 Q1 | 6.02 Million SEK | 0.0% |
| 2019 FY | -6.02 Million SEK | -459.57% |
| 2018 FY | -1.07 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 88.741% |
| Ziccum AB (publ) | -2.13 Million SEK | -163.547% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 70.451% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.072% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 88.721% |
| Mendus AB (publ) | -96.29 Million SEK | 94.151% |
| Genovis AB (publ.) | -43.94 Million SEK | 87.183% |
| Intervacc AB (publ) | -88.16 Million SEK | 93.612% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 127.46% |
| Active Biotech AB (publ) | -33.2 Million SEK | 83.036% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 110.582% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 85.699% |
| Aptahem AB (publ) | 2.9 Million SEK | 293.63% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 98.312% |
| Kancera AB (publ) | -45.69 Million SEK | 87.674% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 98.288% |
| Fluicell AB (publ) | -2.76 Million SEK | -103.836% |
| Saniona AB (publ) | 40.44 Million SEK | 113.924% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 82.36% |
| Biovica International AB (publ) | -58.73 Million SEK | 90.411% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 87.545% |
| AcouSort AB (publ) | -23.98 Million SEK | 76.52% |
| Xintela AB (publ) | -7.8 Million SEK | 27.878% |
| Abliva AB (publ) | -57.24 Million SEK | 90.161% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 97.107% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 93.149% |
| OncoZenge AB (publ) | -12.62 Million SEK | 55.397% |
| 2cureX AB (publ) | -13.4 Million SEK | 57.98% |
| CombiGene AB (publ) | -101.44 Million SEK | 94.448% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -160.62% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 204.296% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.517% |
| Corline Biomedical AB | -17.01 Million SEK | 66.894% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 93.275% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 95.923% |
| I-Tech AB | -83.26 Million SEK | 93.236% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 104.181% |
| Cyxone AB (publ) | -16.67 Million SEK | 66.215% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 89.922% |
| Biosergen AB | -1.88 Million SEK | -199.097% |
| Cantargia AB (publ) | -139.74 Million SEK | 95.97% |
| NextCell Pharma AB | -46.79 Million SEK | 87.963% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 95.651% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 80.832% |
| Nanologica AB (publ) | -9.38 Million SEK | 40.009% |
| SynAct Pharma AB | -61.75 Million SEK | 90.881% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 73.701% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 57.427% |
| LIDDS AB (publ) | -13.51 Million SEK | 58.319% |
| Lipum AB (publ) | -8.46 Million SEK | 33.467% |
| BioInvent International AB (publ) | -236.3 Million SEK | 97.617% |
| Alzinova AB (publ) | -21.22 Million SEK | 73.467% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 91.584% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -8.707% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 93.275% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -510.184% |
| Simris Alg AB (publ) | 85.07 Million SEK | 106.62% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 93.139% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 103.391% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 72.914% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -89.502% |